secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001326190-25-000024
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune to pursue two new indications for pemvidutide: AUD and ALD, Phase 2 trials starting Q2/Q3 2025
--------------------------------------------------------------------------------

- Phase 2 AUD trial for pemvidutide targeting moderate to severe AUD; ~100 subjects, 24 weeks, endpoints include heavy drinking days.
- Phase 2 ALD trial for pemvidutide targeting obesity and ALD; ~100 subjects, 48 weeks, endpoints include liver stiffness and biomarkers.
- Both Phase 2 trials are randomized, double-blind, placebo-controlled designs.
- Altimmune expects to begin the AUD trial in Q2 2025 and the ALD trial in Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619025000024/0001326190-25-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619025000024/alt-20250313x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-25-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer